MX2023002907A - Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300. - Google Patents

Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.

Info

Publication number
MX2023002907A
MX2023002907A MX2023002907A MX2023002907A MX2023002907A MX 2023002907 A MX2023002907 A MX 2023002907A MX 2023002907 A MX2023002907 A MX 2023002907A MX 2023002907 A MX2023002907 A MX 2023002907A MX 2023002907 A MX2023002907 A MX 2023002907A
Authority
MX
Mexico
Prior art keywords
cbp
compounds
heterocyclic compounds
bromodomain inhibitors
formula
Prior art date
Application number
MX2023002907A
Other languages
English (en)
Inventor
Gerd Wohlfahrt
Chandrasekhar Abbineni
Subhendu Mukherjee
Susanta Samajdar
Gore Suraj Tatyasaheb
Ramesh S Senaiar
Renukappa Girish Aggunda
Mikko Myllymaki
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of MX2023002907A publication Critical patent/MX2023002907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona compuestos heterocíclicos de fórmula (I), que son terapéuticamente útiles como inhibidores de CBP/EP300. Estos compuestos son útiles en el tratamiento y/o la prevención de enfermedades o trastornos mediados por CBP y/o EP300 en un individuo. La presente invención también proporciona la preparación de los compuestos y composiciones farmacéuticas que comprenden al menos uno de los compuestos de fórmula (I) o una sal farmacéuticamente aceptable, o un estereoisómero o un tautómero, un N-óxido o un éster de estos.
MX2023002907A 2020-09-09 2021-09-09 Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300. MX2023002907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041038913 2020-09-09
PCT/IB2021/058201 WO2022053967A1 (en) 2020-09-09 2021-09-09 Heterocyclic compounds as cbp/ep300 bromodomain inhibitors

Publications (1)

Publication Number Publication Date
MX2023002907A true MX2023002907A (es) 2023-06-12

Family

ID=80631514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002907A MX2023002907A (es) 2020-09-09 2021-09-09 Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.

Country Status (13)

Country Link
US (1) US20230322724A1 (es)
EP (1) EP4210683A1 (es)
JP (1) JP2023539931A (es)
KR (1) KR20230068412A (es)
CN (1) CN116368128A (es)
AU (1) AU2021341879A1 (es)
CA (1) CA3191529A1 (es)
CL (1) CL2023000670A1 (es)
CO (1) CO2023004420A2 (es)
CU (1) CU20230016A7 (es)
IL (1) IL301225A (es)
MX (1) MX2023002907A (es)
WO (1) WO2022053967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023239227A1 (ko) * 2022-06-10 2023-12-14 주식회사 사피엔스바이오 신규한 화합물 및 이를 유효성분으로 포함하는 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367420B (es) * 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
CA2919948C (en) * 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US20180312496A1 (en) * 2015-07-02 2018-11-01 Orion Corporation Bicyclic heterocycle derivatives as bromodomain inhibitors
JP7160688B2 (ja) * 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
WO2018161876A1 (zh) * 2017-03-08 2018-09-13 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途

Also Published As

Publication number Publication date
CU20230016A7 (es) 2023-10-06
IL301225A (en) 2023-05-01
EP4210683A1 (en) 2023-07-19
CO2023004420A2 (es) 2023-04-27
CN116368128A (zh) 2023-06-30
JP2023539931A (ja) 2023-09-20
KR20230068412A (ko) 2023-05-17
US20230322724A1 (en) 2023-10-12
WO2022053967A1 (en) 2022-03-17
AU2021341879A1 (en) 2023-04-13
CA3191529A1 (en) 2022-03-17
CL2023000670A1 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EP3693369A3 (en) Bromodomain inhibitors
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
HK1116161A1 (en) Substituted amide derivatives as protein kinase inhibitors
CR20230310A (es) Inhibidores de prmt5
MX2022005809A (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr).
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021007247A (es) Derivados de rapamicina.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
MX2019004375A (es) Inhibidores de bromodominios.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors